In our studies, only B2M and not HLA-A expression in tumor biopsies taken during ongoing immunotherapy correlated with clinical benefit, while tumor HLA-A or B2M measured before start of therapy (baseline samples) did not correlate to subsequent clinical outcome. The gene discussed is HLA-A; the disease is neoplasm.